ArticleClinical rheumatology2026
Late recurrence of Kikuchi-Fujimoto disease nine years after initial diagnosis: a case-based review.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kikuchi-Fujimoto disease (KFD), also known as histiocytic necrotizing lymphadenitis, is a rare, benign, and self-limited inflammatory lymphadenitis. It predominantly affects young adults and typically presents with tender cervical lymphadenopathy, low-grade fever, and constitutional symptoms such as malaise, night sweats, and weight loss. Though initially recognized in Asian populations, cases are now reported worldwide. The etiology remains uncertain, but KFD has recognized overlap with autoimmune diseases. Systemic lupus erythematosus (SLE) and Sjögren's disease (SjD) account for most coexisting disorders. We present the case of a woman in her early forties with recurrent cyclical fevers and cervical lymphadenopathy. She had biopsy-proven KFD but showed relapse after a nine-year asymptomatic period after her first manifestation. A case-based review about KFD recurrence was conducted using PubMed/MEDLINE databases following CaBArET guidelines and identified a total of 21 reports for review of the clinical manifestations and treatment approaches of recurrent KFD. Our findings suggest that although KFD is typically self-limited, recurrence may be associated with autoimmune features in selected cases, emphasizing the need for renewed diagnostic vigilance even years after apparent resolution. Although treatment responses in recurrent Kikuchi-Fujimoto disease are heterogeneous, literature evidence and our case suggest that corticosteroids remain first-line, while agents such as hydroxychloroquine or anakinra may offer benefit in steroid-dependent or relapsing cases. However, these remain individualized interventions rather than standardized protocols, and controlled evidence is lacking. Key Points • Kikuchi-Fujimoto disease, although typically self-limited, can relapse after unusually long latency, highlighting the need for continued clinical awareness. • Recurrent presentations may mimic infectious or malignant conditions, often leading to extensive diagnostic work-ups. • Reactive histologic findings at recurrence do not exclude KFD and should be interpreted in the context of prior confirmed disease and clinical evolution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.